Advertisement
ANVS Notícias Sobre o Forex
Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed
Drug platform company Annovis Bio, Inc. (ANVS) announced Wednesday a postponement in the Phase III study data release for buntanetap in Parkinson's Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.
RTTNews
|
461 dias atrás
Annovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's Disease
Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).
RTTNews
|
936 dias atrás
